These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2876385)

  • 1. Opioid receptors for the dynorphin peptides.
    James IF
    NIDA Res Monogr; 1986; 70():192-208. PubMed ID: 2876385
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynorphin A(1-8): stability and implications for in vitro opioid activity.
    Bell KM; Traynor JR
    Can J Physiol Pharmacol; 1998 Mar; 76(3):325-33. PubMed ID: 9673796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible blockade of the kappa-receptor by a newly synthesized dynorphin derivative containing a 3-nitro-2-pyridinesulfenyl group.
    Koike K; Takayanagi I; Hirakura Y; Matsueda R
    Arch Int Pharmacodyn Ther; 1991; 313():33-46. PubMed ID: 1687773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor preference of dynorphin A fragments in the mouse vas deferens determined by different techniques.
    Schulz R; Wüster M; Herz A
    J Pharmacol Exp Ther; 1984 Jul; 230(1):200-4. PubMed ID: 6146706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
    Cox BM; Chavkin C
    Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
    [No Abstract]   [Full Text] [Related]  

  • 6. Benzomorphan sites are ligand recognition sites of putative epsilon-receptors.
    Chang KJ; Blanchard SG; Cuatrecasas P
    Mol Pharmacol; 1984 Nov; 26(3):484-8. PubMed ID: 6149459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
    Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
    J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
    Vig BS; Murray TF; Aldrich JV
    J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family.
    Zhang S; Tong Y; Tian M; Dehaven RN; Cortesburgos L; Mansson E; Simonin F; Kieffer B; Yu L
    J Pharmacol Exp Ther; 1998 Jul; 286(1):136-41. PubMed ID: 9655852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
    Vig BS; Zheng MQ; Murray TF; Aldrich JV
    J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
    Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
    Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid binding properties of brain and peripheral tissues: evidence for heterogeneity in opioid ligand binding sites.
    Leslie FM; Chavkin C; Cox BM
    J Pharmacol Exp Ther; 1980 Aug; 214(2):395-402. PubMed ID: 6248635
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytotoxic effects of dynorphins through nonopioid intracellular mechanisms.
    Tan-No K; Cebers G; Yakovleva T; Hoon Goh B; Gileva I; Reznikov K; Aguilar-Santelises M; Hauser KF; Terenius L; Bakalkin G
    Exp Cell Res; 2001 Sep; 269(1):54-63. PubMed ID: 11525639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in bioassay using selective ligands and selective in vitro preparations.
    Kosterlitz HW; Corbett AD; Gillan MG; McKnight AT; Paterson SJ; Robson LE
    NIDA Res Monogr; 1986; 70():223-35. PubMed ID: 3020423
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the kappa-opioid receptor. A model for receptor activation.
    Paterlini G; Portoghese PS; Ferguson DM
    J Med Chem; 1997 Sep; 40(20):3254-62. PubMed ID: 9379445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the conformational requirements for binding to the kappa-opioid receptor and its subtypes. I. Novel alpha-helical cyclic peptides and their role in receptor selectivity.
    Collins N; Hruby VJ
    Biopolymers; 1994 Sep; 34(9):1231-41. PubMed ID: 7948735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Content of dynorphins and kappa-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice.
    Jamensky NT; Gianoulakis C
    Alcohol Clin Exp Res; 1997 Nov; 21(8):1455-64. PubMed ID: 9394118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynorphin: specific binding to opiate receptors.
    Lee NM; Landahl H
    NIDA Res Monogr; 1986; 71():19-27. PubMed ID: 2879239
    [No Abstract]   [Full Text] [Related]  

  • 20. Characteristics of peptide and alkaloid opiate binding sites in brain and peripheral tissues.
    Cox BM; Leslie FM; Chavkin C
    Adv Biochem Psychopharmacol; 1980; 22():353-62. PubMed ID: 6249080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.